临床分子病理指标检测评估IDH突变型原发性胶质母细胞瘤患者预后的价值

Value of clinical molecular pathologic markers in evaluating prognosis of patients with IDH mutation type primary glioblastoma

目的分析Ki-67增殖指数、MGMT启动子甲基化及TERT启动子突变评估IDH突变型原发性胶质母细胞瘤患者预后的价值。方法对13例IDH突变型原发性胶质母细胞瘤样本分别通过免疫组化检测Ki-67增殖指数、焦磷酸测序检测MGMT启动子甲基化状态和巢式PCR和Sanger测序检测TERT启动子突变状态。结果 Ki-67增殖指数>50%和MGMT启动子低甲基化是IDH突变型原发性胶质母细胞瘤患者预后不良的指标(P<0.05),而TERT启动子突变率在IDH突变型原发性胶质母细胞瘤中较低(2/13),预后评估效果相对较弱(P>0.05)。结论 Ki-67增殖指数和MGMT启动子甲基化可以作为IDH突变型原发性胶质母细胞瘤患者临床预后评估的有效指标。

Objective To analyze the value of Ki-67 proliferation index,MGMT promoter methylation and TERT promoter mutation in evaluating the prognosis of the patients with IDH mutation type primary glioblastoma.Methods Ki-67 proliferation index was detected by immunohistochemistry,MGMT promoter methylation was detected by pyrosequencing,and TERT promoter mutation was detected by nested PCR and Sanger sequencing.Results Ki-67 proliferation index( >50%)and MGMT promoter methylation were the significant indicators of poor prognosis in the patients with IDH mutation(P<0.05),while the mutation rate of TERT promoter was lower in IDH-mutated primary glioblastoma(2/13)with a relative weak efficiency of predicting the prognosis of the patients with IDH mutation type primary glioblastoma(P >0.05).Conclusion Ki-67 proliferation index and MGMT promoter methylation can be used as the effective indicators for evaluating the prognosis of the patients with IDH mutation type primary glioblastoma.